Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Facebook (FB) Tops Q2 EPS by 3c
- Market Wrap: Pending Sales Miss Views in June; FOMC Looks to Jobs for Rate Hike; Facebook Slumps on Mobile Results
- After-Hours Stock Movers 07/29: (UNIS) (SKX) (HOLX) Higher; (QRVO) (WFM) (FB) Lower (more...)
- Whole Foods Market (WFM) Misses Q3 EPS by 1c, Sees FY15 Comp Sales Growth in Low Single Digits
- Fed sees improving economy, job market; September rate hike in view
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pluristem Therapeutics (PSTI) Announces Publication of Study on PLX Cells in Scientific Journal
- Lloyd Blankfein and Michael Bloomberg on the U.S. Economy, Fed Policy and 2016
- Chinese Company Builds Impressive Competitor to Tesla's (TSLA) Upcoming Model 3
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!